Patients with Crohn’s disease display an altered serum IgG glycosylation signature that is detectable many years before clinical diagnosis and is associated with increased levels of pathogenic anti-mannan antibodies. The altered IgG glycoforms activate innate immune cells, in a preclinical phase, promoting the transition to intestinal inflammation.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Torres, J. et al. Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. Gut 65, 1061–1069 (2016). This review article focuses on the main challenges of IBD clinical management, discussing the existence of a preclinical phase and novel strategies for tackling IBD.
Dias, A. M. et al. Metabolic control of T cell immune response through glycans in inflammatory bowel disease. Proc. Natl Acad. Sci. USA 115, E4651–E4660 (2018). This paper reports an alteration in gut mucosa T cell glycosylation associated with UC disease severity.
Dias, A. M. et al. Dysregulation of T cell receptor N-glycosylation: a molecular mechanism involved in ulcerative colitis. Hum. Mol. Genet. 23, 2416–2427 (2014). This paper shows that metabolic supplementation with glycans can repair the deficiency in branched N-glycosylation in mucosal T cells from patients with UC, leading to the suppression of inflammation.
Verhelst, X. et al. Protein glycosylation as a diagnostic and prognostic marker of chronic inflammatory gastrointestinal and liver diseases. Gastroenterology 158, 95–110 (2020). This review article discusses how changes in glycosylation in chronic inflammatory disorders of the gastrointestinal tract can be prognostic and diagnostic markers of disease.
Torres, J. et al. Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis. Gastroenterology 159, 96–104 (2020). This paper identifies a panel of serum markers that are associated with the development of CD years before diagnosis.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Gaifem, J. et al. A unique serum IgG glycosylation signature predicts development of Crohn’s disease and is associated with pathogenic antibodies to mannose glycan. Nat. Immunol. https://doi.org/10.1038/s41590-024-01916-8x (2024).
Rights and permissions
About this article
Cite this article
Changes in the glycosylation of circulating IgG predict future Crohn’s disease onset. Nat Immunol 25, 1526–1527 (2024). https://doi.org/10.1038/s41590-024-01919-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-024-01919-5
